257 related articles for article (PubMed ID: 38487533)
1. Checkpoint CD24 function on tumor and immunotherapy.
Huang S; Zhang X; Wei Y; Xiao Y
Front Immunol; 2024; 15():1367959. PubMed ID: 38487533
[TBL] [Abstract][Full Text] [Related]
2. CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy.
Barkal AA; Brewer RE; Markovic M; Kowarsky M; Barkal SA; Zaro BW; Krishnan V; Hatakeyama J; Dorigo O; Barkal LJ; Weissman IL
Nature; 2019 Aug; 572(7769):392-396. PubMed ID: 31367043
[TBL] [Abstract][Full Text] [Related]
3. Targeting CD24/Siglec-10 signal pathway for cancer immunotherapy: recent advances and future directions.
Li X; Tian W; Jiang Z; Song Y; Leng X; Yu J
Cancer Immunol Immunother; 2024 Jan; 73(2):31. PubMed ID: 38279998
[TBL] [Abstract][Full Text] [Related]
4. CD24: A Novel Target for Cancer Immunotherapy.
Panagiotou E; Syrigos NK; Charpidou A; Kotteas E; Vathiotis IA
J Pers Med; 2022 Jul; 12(8):. PubMed ID: 36013184
[TBL] [Abstract][Full Text] [Related]
5. Discovery of a novel dual-targeting D-peptide to block CD24/Siglec-10 and PD-1/PD-L1 interaction and synergize with radiotherapy for cancer immunotherapy.
Shen W; Shi P; Dong Q; Zhou X; Chen C; Sui X; Tian W; Zhu X; Wang X; Jin S; Wu Y; Chen G; Qiu L; Zhai W; Gao Y
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37344099
[TBL] [Abstract][Full Text] [Related]
6. Nucleophosmin/B23 promotes endometrial cancer cell escape from macrophage phagocytosis by increasing CD24 expression.
Lin CY; Tsai CL; Chao A; Lee LY; Chen WC; Tang YH; Chao AS; Lai CH
J Mol Med (Berl); 2021 Aug; 99(8):1125-1137. PubMed ID: 33954835
[TBL] [Abstract][Full Text] [Related]
7. CD24 targeting with NK-CAR immunotherapy in testis, prostate, renal and (luminal-type) bladder cancer and identification of direct CD24 interaction partners.
Söhngen C; Thomas DJ; Skowron MA; Bremmer F; Eckstein M; Stefanski A; Driessen MD; Wakileh GA; Stühler K; Altevogt P; Theodorescu D; Klapdor R; Schambach A; Nettersheim D
FEBS J; 2023 Oct; 290(20):4864-4876. PubMed ID: 37254618
[TBL] [Abstract][Full Text] [Related]
8. Targeting the GPI transamidase subunit GPAA1 abrogates the CD24 immune checkpoint in ovarian cancer.
Mishra AK; Ye T; Banday S; Thakare RP; Su CT; Pham NNH; Ali A; Kulshreshtha A; Chowdhury SR; Simone TM; Hu K; Zhu LJ; Eisenhaber B; Deibler SK; Simin K; Thompson PR; Kelliher MA; Eisenhaber F; Malonia SK; Green MR
Cell Rep; 2024 Apr; 43(4):114041. PubMed ID: 38573857
[TBL] [Abstract][Full Text] [Related]
9. The Hippo-YAP signaling pathway drives CD24-mediated immune evasion in esophageal squamous cell carcinoma via macrophage phagocytosis.
Zhou X; Yan Z; Hou J; Zhang L; Chen Z; Gao C; Ahmad NH; Guo M; Wang W; Han T; Chang T; Kang X; Wang L; Liang Y; Li X
Oncogene; 2024 Feb; 43(7):495-510. PubMed ID: 38168654
[TBL] [Abstract][Full Text] [Related]
10. Molecular Mechanism of Tumor Cell Immune Escape Mediated by CD24/Siglec-10.
Yin SS; Gao FH
Front Immunol; 2020; 11():1324. PubMed ID: 32765491
[TBL] [Abstract][Full Text] [Related]
11. Novel insights into the function of CD24: A driving force in cancer.
Altevogt P; Sammar M; Hüser L; Kristiansen G
Int J Cancer; 2021 Feb; 148(3):546-559. PubMed ID: 32790899
[TBL] [Abstract][Full Text] [Related]
12. Emerging Immune Checkpoint Molecules on Cancer Cells: CD24 and CD200.
Moon SY; Han M; Ryu G; Shin SA; Lee JH; Lee CS
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894750
[TBL] [Abstract][Full Text] [Related]
13. GATA3 Encapsulated by Tumor-Associated Macrophage-Derived Extracellular Vesicles Promotes Immune Escape and Chemotherapy Resistance of Ovarian Cancer Cells by Upregulating the CD24/Siglec-10 Axis.
Chen C; Zhang L; Ruan Z
Mol Pharm; 2023 Feb; 20(2):971-986. PubMed ID: 36547230
[TBL] [Abstract][Full Text] [Related]
14. Engineering nanoparticles boost TNBC therapy by CD24 blockade and mitochondrial dynamics regulation.
Zhao M; Li J; Chen F; Han Y; Chen D; Hu H
J Control Release; 2023 Mar; 355():211-227. PubMed ID: 36736908
[TBL] [Abstract][Full Text] [Related]
15. CD24 targeting bi-specific antibody that simultaneously stimulates NKG2D enhances the efficacy of cancer immunotherapy.
Han Y; Sun F; Zhang X; Wang T; Jiang J; Cai J; Gao Q; Hezam K; Liu Y; Xie J; Wang M; Zhang J
J Cancer Res Clin Oncol; 2019 May; 145(5):1179-1190. PubMed ID: 30778749
[TBL] [Abstract][Full Text] [Related]
16. Targeting CD24 in Cancer Immunotherapy.
Chen W; Hu Z; Guo Z
Biomedicines; 2023 Nov; 11(12):. PubMed ID: 38137380
[TBL] [Abstract][Full Text] [Related]
17. The biological roles of CD24 in ovarian cancer: old story, but new tales.
Gu Y; Zhou G; Tang X; Shen F; Ding J; Hua K
Front Immunol; 2023; 14():1183285. PubMed ID: 37359556
[TBL] [Abstract][Full Text] [Related]
18. Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity.
Zhang C; Röder J; Scherer A; Bodden M; Pfeifer Serrahima J; Bhatti A; Waldmann A; Müller N; Oberoi P; Wels WS
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599028
[TBL] [Abstract][Full Text] [Related]
19. CD24, A Review of its Role in Tumor Diagnosis, Progression and Therapy.
Ni YH; Zhao X; Wang W
Curr Gene Ther; 2020; 20(2):109-126. PubMed ID: 32576128
[TBL] [Abstract][Full Text] [Related]
20. Overview of CD24 as a new molecular marker in ovarian cancer.
Tarhriz V; Bandehpour M; Dastmalchi S; Ouladsahebmadarek E; Zarredar H; Eyvazi S
J Cell Physiol; 2019 Mar; 234(3):2134-2142. PubMed ID: 30317611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]